1,2-distearoyllecithin has been researched along with Sarcoma 180 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishigori, H; Ogihara-Umeda, I; Sasaki, T | 1 |
| Kojima, S; Ogihara-Umeda, I | 1 |
2 other study(ies) available for 1,2-distearoyllecithin and Sarcoma 180
| Article | Year |
|---|---|
Development of a liposome-encapsulated radionuclide with preferential tumor accumulation--the choice of radionuclide and chelating ligand.
Topics: Animals; Chelating Agents; Cholesterol; Chromium Radioisotopes; Cobalt Radioisotopes; Drug Carriers; Gallium Radioisotopes; Iron Radioisotopes; Ligands; Liposomes; Male; Mice; Mice, Inbred Strains; Phosphatidylcholines; Sarcoma 180; Time Factors; Tissue Distribution | 1992 |
Cholesterol enhances the delivery of liposome-encapsulated gallium-67 to tumors.
Topics: Animals; Cholesterol; Drug Carriers; Gallium Radioisotopes; Liposomes; Male; Mice; Neoplasm Transplantation; Phosphatidylcholines; Sarcoma 180; Tissue Distribution | 1989 |